Andrew Loblaw, Prostate Cancer researcher at Sunnybrook Health Sciences Centre, shared a post on X:
“I believe 2 fractions will be confirmed to be most effective, cost effective and best tolerated. Multiple RCTs accruing or maturing (HERMES, FORT, iSMART, SABR-DUAL).
I still doubt whether single fraction SBRT as a curative treatment will as good (but maybe fine palliation).”
More Posts Featuring A. Loblaw.